Findings support the continued use of TNF inhibitor monotherapy in individuals with immune-mediated inflammatory diseases. In the study, these patients had a lower risk of hospitalization or death caused by COVID-19 than patients on other commonly prescribed treatment regimens
![](https://www.the-rheumatologist.org/wp-content/uploads/2020/03/GettyImages_Coronavirus_500x250-150x150.jpg)